Literature DB >> 14971700

The effect of repeated half-yearly diethylcarbamazine mass treatment on Wuchereria bancrofti infection and transmission in two East African communities with different levels of endemicity.

Paul E Simonsen1, Dan W Meyrowitsch, Dunstan A Mukoko, Erling M Pedersen, Mwele N Malecela-Lazaro, Rwehumbiza T Rwegoshora, John H Ouma, Naftal Masese, Walter G Jaoko, Edwin Michael.   

Abstract

The effect of repeated half-yearly mass treatment with diethylcarbamazine (DEC, 6 mg/kg body weight) on infection and transmission of Wuchereria bancrofti was assessed and compared in communities with high and low endemicity in eastern Africa, with pretreatment microfilaria (mf) and circulating filarial antigen (CFA) prevalences of 29.4% and 53.2% in the high endemicity community and 3.1% and 18.7% in the low endemicity community, respectively. Human infection was monitored by repeated cross-sectional surveys, and transmission by weekly light trap collection of vector mosquitoes in selected houses in each community. Treatments resulted in a progressive decrease in microfilaremia and circulating antigenemia in both communities, with relative reductions being considerably higher for mf than for CFA. Among pretreatment mf-positive individuals, more than 60% were diagnosed as mf negative and mean mf intensities were reduced by 99% in both communities after two treatment rounds. In contrast, only moderate reductions were seen in circulating antigenemia among pretreatment CFA-positive individuals, with mean intensities still being 24-39% of pretreatment values after two treatment rounds. Among the pretreatment mf/CFA-positive individuals, clearance to a CFA-negative status was negligible. Complete CFA clearance was only observed among pretreatment CFA-positive but mf negative individuals who also had much lower initial mean CFA levels than the mf-positive individuals. After treatment, the intensity of transmission decreased in the high-endemicity community, but this appeared mainly to be a consequence of a drought-induced reduction in vector density rather than to reduced mf load in the human population, since the proportion of mosquitoes carrying infective larvae was not reduced. No change in transmission or mosquito infectivity was observed after treatment in the low-endemicity community. Implications of these observations for the control of Bancroftian filariasis are discussed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14971700

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  11 in total

1.  Is the current decline in malaria burden in sub-Saharan Africa due to a decrease in vector population?

Authors:  Dan W Meyrowitsch; Erling M Pedersen; Michael Alifrangis; Thomas H Scheike; Mwelecele N Malecela; Stephen M Magesa; Yahya A Derua; Rwehumbiza T Rwegoshora; Edwin Michael; Paul E Simonsen
Journal:  Malar J       Date:  2011-07-13       Impact factor: 2.979

2.  Lymphatic filariasis control in Tanzania: effect of repeated mass drug administration with ivermectin and albendazole on infection and transmission.

Authors:  Paul E Simonsen; Erling M Pedersen; Rwehumbiza T Rwegoshora; Mwelecele N Malecela; Yahya A Derua; Stephen M Magesa
Journal:  PLoS Negl Trop Dis       Date:  2010-06-01

Review 3.  Lymphatic Filariasis in India : Problems, Challenges and New Initiatives.

Authors:  V K Agrawal; V K Sashindran
Journal:  Med J Armed Forces India       Date:  2011-07-21

4.  Current evidence on the use of antifilarial agents in the management of bancroftian filariasis.

Authors:  Sumadhya Deepika Fernando; Chaturaka Rodrigo; Senaka Rajapakse
Journal:  J Trop Med       Date:  2010-12-30

5.  Epidemiological and entomological evaluations after six years or more of mass drug administration for lymphatic filariasis elimination in Nigeria.

Authors:  Frank O Richards; Abel Eigege; Emmanuel S Miri; Alphonsus Kal; John Umaru; Davou Pam; Lindsay J Rakers; Yohanna Sambo; Jacob Danboyi; Bako Ibrahim; Solomon E Adelamo; Gladys Ogah; Danjuma Goshit; O Kehinde Oyenekan; Els Mathieu; P Craig Withers; Yisa A Saka; Jonathan Jiya; Donald R Hopkins
Journal:  PLoS Negl Trop Dis       Date:  2011-10-11

6.  An evaluation of coverage and compliance of mass drug administration 2006 for elimination of lymphatic filariasis in endemic areas of gujarat.

Authors:  Pradeep Kumar; Pb Prajapati; Deepak Saxena; Abhay B Kavishwar; George Kurian
Journal:  Indian J Community Med       Date:  2008-01

7.  Global eradication of lymphatic filariasis: the value of chronic disease control in parasite elimination programmes.

Authors:  Edwin Michael; Mwele N Malecela; Mihail Zervos; James W Kazura
Journal:  PLoS One       Date:  2008-08-13       Impact factor: 3.240

8.  An evaluation of mass drug administration compliance against filariasis of tikamgarh district of madhya pradesh-a household-based community study.

Authors:  Sandeep Singh; Meena Patel; Sugriv Singh Kushwah
Journal:  J Family Med Prim Care       Date:  2013-04

9.  Prevalence of Lymphatic Filariasis and Treatment Effectiveness of Albendazole/ Ivermectin in Individuals with HIV Co-infection in Southwest-Tanzania.

Authors:  Inge Kroidl; Elmar Saathof; Lucas Maganga; Petra Clowes; Leonard Maboko; Achim Hoerauf; Williams H Makunde; Antelmo Haule; Prisca Mviombo; Bettina Pitter; Neema Mgeni; Joseph Mabuye; Dickens Kowuor; Upendo Mwingira; Mwelecele N Malecela; Thomas Löscher; Michael Hoelscher
Journal:  PLoS Negl Trop Dis       Date:  2016-04-12

10.  Community-based trial of annual versus biannual single-dose ivermectin plus albendazole against Wuchereria bancrofti infection in human and mosquito populations: study protocol for a cluster randomised controlled trial.

Authors:  Dziedzom K de Souza; Collins S Ahorlu; Susan Adu-Amankwah; Joseph Otchere; Sedzro K Mensah; Irene A Larbi; George E Mensah; Nana-Kwadwo Biritwum; Daniel A Boakye
Journal:  Trials       Date:  2017-10-02       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.